Autolus Therapeutics (AUTL) Projected to Post Quarterly Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) is projected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $2.98 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Autolus Therapeutics Price Performance

AUTL stock opened at $1.82 on Tuesday. The business’s 50-day moving average is $2.07 and its two-hundred day moving average is $2.96. The firm has a market capitalization of $484.29 million, a P/E ratio of -1.50 and a beta of 2.07. Autolus Therapeutics has a 1 year low of $1.68 and a 1 year high of $6.63.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AUTL. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Buy” and an average target price of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.